Şunu aradınız:: at least 1 way side camera fualty (İngilizce - Maltaca)

at least 1 day,
mill-inqas jum

at least 1 mutation
tal-anqas mutazzjoni 1

length: at least 1 000 mm
tul: tal-inqas 1 000 mm

use prohibited at least 1 day before slaughter.
użu pprojbit mill-inqas jum wieħed qabel it-tbiċċir

(at least 1 in 10 people are affected)
(mill-inqas 1 f’10 persuni huma affettwati)

very common side effects (at least 1 in 10 patients): headache.
29 effetti sekondarji komuni ħafna (għallinqas 1 f' 10 pazjenti): uġigħ ta 'ras.

common side effects (occurring in at least 1 in 100 patients) are:
effetti sekondarji komuni (jseħħu mill- anqas f’ 1 minn kull 100 pazjent) huma:

rare side effects (occurring in at least 1 in 10,000 patients) are:
effetti sekondarji mhux komuni (iseħħu f' mill- anqas 1 f' 1, 000 pazjent) huma:

uncommon side effects (occurring in at least 1 in 1,000 patients) are:
effetti sekondarji mhux komuni (jseħħu mill-anqas f’1 minn kull 1,000 pazjent) huma:

common side effects are experienced in less than 1 in 10 patients but in at least 1 per 100 patients.
effetti sekondarji komuni ħafna li jħosshom mill- inqas 1 minn kull 10 pazjenti effetti sekondarji komuni li jħosshom inqas minn pazjent 1 kull 10 pazjenti iżda f’ aktar minn 1 kull 100 pazjent.

uncommon side effects are experienced in less than 1 in 100 patients but in at least 1 per 1,000 patients.
effetti sekondarji mhux komuni li jħosshom inqas minn 1 kull 100 pazjent iżda f’ aktar minn 1 kull 1, 000 pazjent.

very common side effects (seen in at least 1 in every 10 patients treated in clinical trials):
effetti sekondarji komuni ħafna (osservati f’ta’ l-inqas pazjent wieħed minn kull 10 ikkurati fil-provi kliniċi):

commonly reported side effects (at least 1 in every 100 patients, but less than 1 in every 10 patients):
effetti sekondarji rrappurtati komuni (mill- anqas 1 f’ kull 100 pazjent, iżda anqas minn 1 f’ kull 10 pazjenti):

during each infusion and for at least 1 hour afterwards, your condition will be checked regularly for early signs of a possible infusion-related side effect.
waqt kull infużjoni u għal mill-inqas siegħa wara, il-kundizzjoni tiegħek ser tkun iċċekkjata regolarment għal sinjali bikrin ta’ effett sekondarju marbut ma’ l-infużjoni.

in studies, the most commonly reported side effects (occurring in at least 1 in 10 individuals) were at the injection site.
fl- istudji, l- aktar effetti sekondarji komuni rrapportati (li jseħħu f' għallinqas individwu 1 minn kull 10) seħħew fil- post fejn ingħatat l- injezzjoni.

the most common side effects reported in at least 1 in 10 patients receiving tygacil are: • nausea, vomiting, diarrhoea.
l- aktar effetti sekondarji komuni rapportati f 'ta ’ lanqas pazjent 1 f' 10 li kienu qed jirċievu tygacil huma: • nawsja, rimettar, dijarea

rarely reported side effects (at least 1 in every 10,000 patients, but less than 1 in every 1,000 patients): pneumonia
effetti sekondarji rrappurtati b’mod rari (mill-anqas 1 f’kull 10,000 pazjent, iżda anqas minn 1 f’kull 1,000 pazjent): pulmonite

rarely reported side effects (at least 1 in every 10,000 patients, but less than 1 in every 1,000 patients): pneumonia rod
(tibda jew tmur għall- agħar), żieda fl- għaraq, żieda fil- bżonn li tgħaddi l- awrina, movimenti ta ’ tregħid żgħir, nuqqas ta ’ sensittività biex tħoss, artrite.

when a side effect is described as “ common” this means that it has been reported in at least 1 in every 100 patients but less than 1 in every 10 patients.
filwaqt li meta xi effett sekondarju huwa deskritt bħala wieħed "komuni" dan ifisser li kien irrappurtat f’ mill- inqas pazjent 1 minn kull 100 pazjent iżda inqas minn pazjent 1 minn kull 10 pazjenti.

 463 uncommonly reported side effects (at least 1 in every 1000 patients, but less than 1 in every 100 patients): bacterial infection and feeling of pins and needles.
effetti sekondarji irrappurtati b’ mod mhux komuni (mill- anqas 1 f’ kull 1, 000 pazjent, iżda anqas minn 1 f’ kull 100 pazjent): infezzjoni tal- batteri u sensazzjoni ta ’ tingiż.